Drug intelligence / Profile preview

gypensapogenin I

Development stage: Preclinical
Modality: Small Molecules
Administration: Oral

Overview

Gypensapogenin I is a biologically active saponin compound extracted from the traditional Chinese herbal medicine *Gynostemma pentaphyllum*. It has demonstrated therapeutic potential in the treatment of ulcerative colitis by reducing intestinal inflammation and modulating the gut microbiota. Mechanistically, gypensapogenin I targets AKT serine/threonine kinase 1 (AKT1), thereby modulating the PI3K/AKT signaling pathway. Research indicates its efficacy in both in vivo and in vitro models of intestinal disease, where it helps restore microbial balance and suppress inflammatory responses.

Other names: GI

Targets

NOTCH (Neurogenic locus notch homolog protein 3)GSK3 (Glycogen synthase kinase 3 beta)AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)CTNNB1 (Beta-catenin)

Beyond the preview

Go deeper on gypensapogenin I.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on gypensapogenin I.

Explore the full profile